Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s share price was up 13.1% on Wednesday . The company traded as high as $6.99 and last traded at $7.05. Approximately 16,281 shares changed hands during trading, a decline of 62% from the average daily volume of 43,037 shares. The stock had previously closed at $6.23.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on VALN shares. HC Wainwright reissued a "buy" rating and set a $17.00 price target on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim dropped their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th.
Read Our Latest Report on VALN
Valneva Trading Up 2.2%
The firm has a market capitalization of $660.30 million, a price-to-earnings ratio of -6.53 and a beta of 1.74. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.12 and a current ratio of 2.70. The business has a fifty day moving average price of $6.14 and a 200 day moving average price of $6.31.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.27. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. The firm had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. As a group, equities analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.
Hedge Funds Weigh In On Valneva
A hedge fund recently bought a new stake in Valneva stock. GAMMA Investing LLC bought a new position in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,964 shares of the company's stock, valued at approximately $94,000. 11.39% of the stock is owned by institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
